TDO2 and cancer: Another systemic change observed in cancer patients is an altered tryptophan metabolism, primarily mediated by increased tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase 1 (IDO1) activities [23].